Altum Sequencing Exhibits at EHA 2026 Congress in Stockholm — A First Milestone for the Company
- Altum Sequencing
- Jun 17
- 2 min read
Company debuts its own booth at the European Hematology Association Congress, strengthening its presence in the international hematology community
This year marked a special milestone for Altum Sequencing: for the first time, the company exhibited with its own stand at the European Hematology Association (EHA) Congress, held in Stockholm.
Over four days, the Altum team had the opportunity to meet with clinicians, principal investigators, pharmaceutical companies, partners, and collaborators from across the international hematology community.
Strong Interest in MRD and Molecular Monitoring
Throughout the congress, Altum Sequencing observed strong and growing interest in Minimal Residual Disease (MRD) and molecular monitoring, reinforcing the company's conviction that molecular insights will play an increasingly important role in both clinical practice and drug development.
"EHA was an opportunity to strengthen existing collaborations, establish new relationships, and continue advancing our mission: helping clinicians track cancer more precisely through molecular monitoring," the Altum Sequencing team noted.
A Milestone Built on Strong Foundations
Altum Sequencing's presence at EHA 2026 reflects the vision behind the company since its founding. The milestone was made possible by the leadership of the company's founders, Joaquín Martínez, MD, PhD, MBA, and Rosa Ayala, MD, PhD, alongside the leadership of CEO Marina Planas and the dedication of the entire Altum team.
Representing Altum Sequencing on the ground in Stockholm were Isabel Espejo Díaz, PhD, Ángel Villota Román, and Ricardo Errazquin Ciudad, whose work at the booth helped make the congress a success for the company.
From Europe to the Globe
For Altum Sequencing, EHA 2026 was more than a scientific congress — it was a chance to connect directly with the clinicians, researchers, and industry partners shaping the future of hematology and precision oncology. The company extends its thanks to everyone who visited the stand, shared their perspectives, and explored opportunities for collaboration.
As Altum Sequencing continues to grow its footprint across Europe and beyond, its participation at EHA 2026 marks another step in its journey: developing molecular monitoring technology in Europe, with the ambition to impact cancer patients worldwide.
The journey continues. From Europe to the globe.
Altum Sequencing is a precision oncology company based in Madrid, Spain, developing ctDNA-based liquid biopsy technology for cancer monitoring. Spun off from Hospital Universitario 12 de Octubre, the company's platform supports minimal residual disease detection and longitudinal treatment monitoring across a range of oncology indications.
Comments